Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity

Journal of Pharmacological Sciences

Volumn 114, Issue 3, 2010, Pages 248-261

  Takeuchi, Koji ^a   Kato, Shinichi ^a   Amagase, Kikuko ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

EP receptor subtype; Function; Gastrointestinal tract; Mucosal protection; Prostaglandin E

Indexed keywords

11 DEOXYPROSTAGLANDIN E2; 17 PHENYLPROSTAGLANDIN E2; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; ALCOHOL; BUTAPROST; CAPSAICIN; CJ 42794; HYDROCHLORIC ACID; INDOMETACIN; ONO AE 1 329; ONO AE 1 734; ONO AE 3 208; ONO AE 5 599; ONO AE 829; ONO NT 012; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SULPROSTONE; UNCLASSIFIED DRUG;

CELL PROTECTION; COLITIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; ESOPHAGUS INJURY; GASTROINTESTINAL MUCOSA; HUMAN; INTESTINE INJURY; INTESTINE ISCHEMIA; LOW DRUG DOSE; NONHUMAN; PROTEIN FUNCTION; REFLUX ESOPHAGITIS; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE CONTRACTION; STOMACH INJURY; STOMACH LESION; STOMACH PROTECTION; STOMACH ULCER; STRESS; ULCER HEALING; ULCEROGENESIS;

EID: 78649412513     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R06CR     Document Type: Review

References (95)

1. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: Current knowledge and proposed mechanisms. Am J Physiol. 1983;245:G601-G623.
2. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979;77:433-443.
3. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P. Prostanoids and their receptors. In: Emmett JC, editor. Comprehensive medicinal chemistry, membranes & receptors. Oxford: Pergamon Press; 1990. p. 643-714.
4. Sugimoto Y. Namba T, Honda A, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem. 1992;267:6463-6466.
5. Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, et al. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem. 1993;27:20175-20178.
6. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structure, properties and functions. Physiol Rev. 1999;79:1193-1226.
7. Takeuchi K, Ukawa H, Kato S, Furukawa O, Araki H, Sugimoto Y, et al. Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E receptor subtype EP3. Gastroenterology. 1999;117:1128-1135.
8. 2 in rat stomachs. Alimental Pharmacol Ther. 2000;14 Suppl 1:18-25.
9. Takeuchi K, Yagi K, Kato S, Ukawa H. Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats. Gastroenterology. 1997;113:1553-1559.
10. Takeuchi K, Araki H, Komoike Y, Umeda M, Suzuki K. Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: A study using rats and knockout mice. J Pharmacol Exp Ther. 2001;297:1160-1165.
11. Suzuki K, Araki H, Mizoguchi H, Takeuchi K. E type prostaglandin inhibits indomethacin-induced gastric lesions in rats through EP1 receptors: Importance of antigastric motility action. Digestion. 2001;63:92-101.
12. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci. 2002;47:894-904.
13. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med.1999;159:649-657.
14. Nagahama K, Yamato M, Kato S, Takeuchi K. Protective effect of lafutidine, a novel H2 receptor antagonist, on acid reflux esophagitis in rats through capsaicin-sensitive afferent neurons. J Pharmacol Sci. 2003;93:55-61.
15. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol. 1991;55:437-451.
16. 2 on a rat model of esophagitis mediated by EP1 receptors: Relation to pepsin secretion. Digestion. 2005; 72:109-118.
17. Kotani T, Kobata A, Nakamura E, Amagase K, Takeuchi K. Roles of COX-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach. J Pharmacol Exp Ther. 2006;316:547-555.
18. Takahira Y, Izumi N, Tanaka A, Takeuchi K. Importance of prostacyclin/IP receptors in maintenance of mucosal integrity of mouse stomachs under cold-restraint stress conditions. Gastroenterology. 2007;132:A-412.
19. Tanigami M, Hatazawa R, Ogura M, Ito Y, Tanaka A, Takeuchi K. Adaptive gastric cytoprotection is mediated by prostaglandin E receptor EP1 but not EP4 subtype. Gastroeterology. 2007;132: A-410.
20. Robert A, Nezamis JE, Lancaster C, Davis JP, Field SO, Hanchar AJ. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol. 1983; 245:G113-G121.
21. Takeuchi K, Kato S, Ogawa Y, Takeeda M, Nakashima M, Matsumoto M. Facilitation by endogenous prostaglandins of capsaicin-induced gastric protection through EP2 and IP receptors. J Pharmacol Exp Ther. 2003;304:1055-1062.
22. Holzer P. Neural emergency system in the stomach. Gastroenterology. 1998;114:828-839.
23. Takeuchi K, Niida H, Matsumoto J, Ueshima K, Okabe S. Gastric motility changes in capsaicin-induced cytoprotection in the rat stomach. Jpn J Pharmacol. 1991;55:147-155.
24. Uchida M, Yano S, Watanabe K. The role of capsaicin-sensitive afferent nerves in protective effect of capsaicin against absolute ethanol-induced gastric lesions in rats. Jpn J Pharmacol. 1991;55: 279-282.
25. Boku K, Ohno T, Saeki T, Hayashi H, Hayashi I, Katori M, et al. Adaptive cytoprotection mediated by prostaglandin I2 is attributable to sensitization of CRGP-containing sensory nerves. Gastroenterology. 2001;120:134-143.
26. Takeuchi K, Ueki S, Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci. 1986;31:1114-1121.
27. Farber JL, Chien KR, Mittnacht S Jr. Myocardial ischemia: the pathogenesis of irreversible cell injury in ischemia. Am J Pathol. 1981;102:271-281.
28. Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003;75:S644-S668.
29. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol. 1999;128:165-1666.
30. Hiratsuka T, Futagami S, Tatsuguchi A, Ueski N, Suzuki K, Shinji Y, et al. COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice. Scand J Gastroenterol. 2005;40:903-913.
31. Konturek SJ, Robert A.Cytoprotection of canine gastric mucosa by prostacyclin: possible mediation by increased mucosal blood flow. Digestion. 1982;25:155-163.
32. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108: 25-30.
33. Yokotani K, Okuma Y, Osumi Y. Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anesthetized rats. Br J Pharmacol. 1996; 117:653-656.
34. Takahashi S, Takeuchi K, Okabe S. EP4 receptor mediation of prostaglandin E2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol. 1999;58:1997-2002.
35. Ohno T, Katori M, Majima M, Saeki T, Boku K, Nishiyama K, et al. Dilatation and constriction of rat gastric mucosal microvessels through prostaglandin EP2 and EP3 receptors. Aliment Pharmacol Ther. 1999;13:1243-1250.
36. 3 secretion in stomach. J Physiol Pharmacol. 2006;57:661-676.
37. 2 on gastric acid secretion through different EP receptor subtypes in the rat. Am J Physiol. 2005;289:G64-G69.
38. Mersereau WA, Hinchey EJ. Role of gastric mucosal folds in formation of focal ulcers in the rat. Surgery. 1982;91:150-155.
39. Takeuchi K, Matsumoto J, Ueshima K, Okabe S. Gastric motility changes in the cytoprotective action of N-ethyl-maleimide and capsaicin in the rat stomach. In: Tsuchiya M, editor. Frontier of mucosal immunology. New York: Elsevier Science Publisher; 1991. p. 581-584.
40. Takeuchi K, Ueshima K, Hironaka Y, Fujioka Y, Matsumoto J, Okabe S. Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Digestion. 1991;49:175-184.
41. Okada M, Niida H, Takeuchi K, Okabe S. Role of prostaglandin deficiency in pathogenic Mechanism of gastric lesions induced by indomethacin in rats. Dig Dis Sci. 1989;34:694-702.
42. 2α. Prostaglandins Leukot Med. 1982;8:287-300.
43. Ding M, Kinoshita Y, Kishi K, Nakata H, Hassan S, Kawanami C, et al. Distribution of prostaglandin E receptors in the rat gastrointestinal tract. Prostaglandins. 1997;53:199-216.
44. Morimoto K, Sugimoto Y, Katsuyama M, Oida H, Tsuboi K, Kishi K, et al. Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol. 1997;272:G681-G687.
45. Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy; are neutrophils the culpris? Trend Pharmacol Sci. 1992;3:129-131.
46. Roma A, Armstrong I. Investigation of inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br J Pharmacol. 1995;116:2903-2908.
47. Melange R, Gentry C, Toseland N, Smith PH, Fuller J. Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat. Dig Dis Sci. 1995;40:2694-2703.
48. Takeuchi K, Ueki S, Tanaka H. Endogenous prostaglandins in gastric alkaline response in the rat stomach after damage. Am J Physiol. 1986;250:G842-G849.
49. Matsumoto J, Takeuchi K, Ueshima K, Okabe S. Role of capsaicin- sensitive afferent neurons in mucosal blood flow response of rat stomach induced by mild irritants. Dig Dis Sci. 1992;37: 1336-1344.
50. Hirata T, Ukawa H, Yamakuni H, Kato S, Takeuchi K. Cyclooxygenase isozymes in acute mucosal ulcerogenic and functional responses following barrier disruption in rat stomachs. Br J Pharmacol. 1997;122:447-454.
51. Takeeda M, Yamato M, Kato S, Takeuchi K. Cyclooxygenase isozymes involved in adaptive functional responses in rat stomachs following barrier disruption. J Pharmacol Exp Ther. 2003; 307:713-719.
52. Takeuchi K, Ogawa Y, Kagawa S, Ukawa H. Gastric ulcerogenic response following barrier disruption in knockout mice lacking prostaglandin EP1 receptors. Aliment Pharmacol Ther. 2002;16: 74-82.
53. Komoike Y, Nakashima M, Nakagiri A, Takeuchi K. Prostaglandin EP1 but not IP receptors involved in mucosal blood flow response of mouse stomachs following barrier disruption. Digestion. 2003;67:186-194.
54. 3 transport by luminal acid in the frog in vitro. Am J Physiol. 1984;246:G235-G246.
55. 3 transport: Characteristics and proposed role in acidity regulation and mucosal protection. Am J Physiol. 1982;242:G183-G193.
56. Hirata T, Ukawa H, Kato S, Takeuchi K. Effects of selective cyclooxygenase-2 inhibitors on acid-induced alkaline secretory and mucosal ulcerogenic responses in the rat duodenum. Life Sci. 1997;61:1603-1611.
57. Takeuchi K, Kagawa S, Mimaki H, Kawauchi S. COX and NOS isozymes involved in duodenal bicabonate response induced by mucosal acidification in rats. Dig Dis Sci. 2002;47:2116-2124.
58. Aoi M, Aihara E, Nakashima M, Takeuchi K. Participation of prostaglandin receptor EP4 subtype in duodenal bicarbonate secretion in rats. Am J Physiol. 2004;287:G96-G103.
59. Hogan DL, Yao B, Steinbach JH, Isenberg JI. The enteric nervous system modulates mammalian duodenal mucosal bicarbonate secretion. Gastroenterology. 1993;105:410-417.
60. Takeuchi K, Matsumoto J, Ueshima K, Okabe S. Role of capsaicin- sensitive afferent neurons in alkaline secretory response to luminal acid in the rat duodenum. Gastroenterology. 1991;101: 954-961.
61. Takeuchi K, Furukawa O, Tanaka H, Okabe S. A new model of duodenal ulcers induced in rats by indomethacin plus histamine. Gastroenterology. 1986;90:636-645.
62. Aihara E, Nomura Y, Sasaki Y, Ise F, Kita K, Takeuchi K. Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci. 2007;80:2446-2453.
63. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997;112:109-117.
64. Kunikata T, Araki H, Takeeda M, Kato S, Takeuchi K. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes. J Physiol Paris. 2001;95:157-163.
65. Boughton-Smith N, Evans SM, Laszlo F, Whittle BJR, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol. 1993;110: 1189-1195.
66. Konaka A, Tanaka A, Kato S, Nishijima M, Takeuchi K. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced intestinal lesions in rats. J Physiol Pharmacol. 1999;50:25-38.
67. Tanaka A, Kunikata T, Konaka A, Kato S, Takeuchi K. Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol. 1999; 50:405-417.
68. 2 stimulates rat and human colonic mucin exoxcytosis via the EP4 receptor. Gastroenterology. 1999;117:1352-1362.
69. Bunce KT, Spraggs CF. Prostanoids stimulation of anion secretion in guinea-pig gastric and ileum mucosa is mediated by different receptors. Br J Pharmacol. 1990;101:889-895.
70. Takeuchi K, Hase S, Mizoguchi H, Miyazawa T, Tanaka A. Protection by aspirin of indomethacin-induced small intestinal damage in rats: mediation by salicylic acid. J Physiol Paris. 2001; 95:51-57.
71. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion. 2002;66:30-41.
72. Simmonds NJ, Rampton DS: Inflammatory bowel disease - a radical view. Gut. 1993;34:865-868.
73. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995; 109:1344-1367.
74. Hirata I, Murano M, Nitta M, Sasaki S, Toshina K, Maemura K, Katsu K. Estimation of mucosal inflammatory mediators in rat DSS-induced colitis: Possible role of PGE2 in protection against mucosal damage. Digestion. 2001;63 Suppl 1:73-80.
75. 2 receptor subtype with rat dextran sodium sulphate colitis: Colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol. 2002;56: 6-75.
76. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883-893.
77. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci. 2007;52:2095-2103.
78. 2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur J Pharmacol. 2009;603:120-132.
79. Borody TJ, Warren EF, Leis S, Surace R, Ashma O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
80. Okayama M, Tsubouchi R, Nishio H, Kato S, Takeuchi K. Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis. Digestion. 2004;70: 240-249.
81. Rumi G, Tsubouchi R, Okayama M, Kato S, Mozsik G, Takeuchi K. Protective effect of lactulose on dextran sulfate sodiuminduced colonic inflammation in rats. Dig Dis Sci. 2004;49: 1466-1472.
82. Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, Takeuchi K. Prophylactic effect of irsogladine maleate against indometha cin-induced small intestinal lesions in rats. Dig Dis Sci. 2008; 53:2657-2666.
83. Ukawa H, Yamakuni H, Kato S, Taleuchi K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on gastric ulcerogenic and healing response in experimental animals. Dis Dis Sci. 1998;43:2003-2011.
84. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 2001;49:443-453.
85. 2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol. 2007;293: G788-G797.
86. Mizuno H, Akamatsu T, Kasuga M. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112: 387-397.
87. Takeuchi K, Tanaka A, Kato S, Aihara E, Amagase K. Effect of CJ-42794, a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther. 2007;322:903-912.
88. Hatazawa R, Ohno R, Tanigami M, Tanaka A, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-Induced small intestinal lesions in rats. J Pharmacol Exp Ther. 2006;318:691-699.
89. Takeuchi K, Tanigami M, Amagase K, Ochi A, Hatazawa R. Endogenous PGE2 accelerates healing of indomethacin-induced small intestinal lesions through up-regulation of VEGF expression via activation of EP4 receptors. J Gastroentrol Hepatol. 2010;25 Suppl 1:S67-S74.
90. Moncada S, Ferreira SH, Vane JR. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature. 1973;246:215-219.
91. Williams TJ, Jose PJ. Mediation of increased vascular permeability after complement activation. J Exp Med. 1981;153,136-153.
92. Wedgwood KR, Farmer RC, Reber HA. A model of hemorrhagic pancreatitis in cats: Role of 16,16-dimethyl PGE2• Gastroenterology. 1986;90:32-39.
93. 2 aggravates gastric mucosal injury induced by histamine in rats: Possible role of the increased mucosal vascular permeability. Gastroenterology. 1987;93:1276-1286.
94. 2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci.2003;74:629-641.
95. Szabo S. Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol. 1991;13 Suppl 2:S21-S34.